7
项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的临床试验Aprocitentan 治疗难治性高血压(RHT)受试者的多中心、盲法、随机、平行组、 3 期研究
这项研究的目的是评价在难治性高血压患者中在其他抗高血压药物治疗的基础上添加新药Aprocitentan在的降血压作用以及这种作用的持久性。
Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans
The creole study is a A Multi-centre, multinational, randomised single-blind, parallel group, three-armed superiority trial which is aimed at comparing the efficacy of three "free" combinations of two anti-hypertensive agents on 24 hour ambulatory systolic blood pressure (ASBP) in black African hypertensive patients.
A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160 and less than 200 mmHg).
100 项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的临床结果
100 项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的转化医学
100 项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的专利(医药)
1
项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的文献(医药)2009-06-15·The Medical letter on drugs and therapeutics
1
项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的新闻(医药)转自:国家药监局 编辑:wangxinglai20042023年12月26日,国家药监局发布了第74批次仿制药一致性评价参比制剂目录,其中新增品种32个、变更及增加持证商品种28个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定,现发布仿制药参比制剂目录(第七十四批)。涉及品种:替戈拉生片、维奈克拉片、拉替拉韦钾片、茚达格莫吸入粉雾剂(II)、复方肝素钠尿囊素凝胶、维生素B12注射液、盐酸沙丙蝶呤散剂、苯磺酸氨氯地平口服溶液、氨氯地平缬沙坦氢氯噻嗪片、缬沙坦口崩片、匹伐他汀钙口崩片、茚达特罗莫米松吸入粉雾剂(I)、二十碳五烯酸乙酯软胶囊、注射用两性霉素B脂质体、硝普钠注射液、米氮平片、呋喃妥因胶囊、阿莫西林克拉维酸钾干糖浆(14:1)等;仿制药参比制剂目录(第74批) (扫描二维码下载附件) 仿制药参比制剂目录(第74批)
100 项与 苯磺酸氨氯地平/缬沙坦/氢氯噻嗪 相关的药物交易